ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 11
Dec.  2020
Turn off MathJax
Article Contents
Gabriela Silvia Gheorghe, Andreea Simona Hodorogea, Andrei Cristian Dan Gheorghe, Ioan Tiberiu Nanea, Ana Ciobanu. Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation. J Geriatr Cardiol 2020; 17(11): 704-709. doi: 10.11909/j.issn.1671-5411.2020.11.002
Citation: Gabriela Silvia Gheorghe, Andreea Simona Hodorogea, Andrei Cristian Dan Gheorghe, Ioan Tiberiu Nanea, Ana Ciobanu. Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation. J Geriatr Cardiol 2020; 17(11): 704-709. doi: 10.11909/j.issn.1671-5411.2020.11.002

Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation

doi: 10.11909/j.issn.1671-5411.2020.11.002
More Information
  • loading
  • [1]
    Faggiano P, Antonini-Canterin F, Baldessin F, et al. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound 2006; 4: 27. doi: 10.1186/1476-7120-4-27
    [2]
    Iunga B, Baronb G, Butchartc EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231-1243. doi: 10.1016/S0195-668X(03)00201-X
    [3]
    Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739-2791. doi: 10.1093/eurheartj/ehx391
    [4]
    Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607. doi: 10.1056/NEJMoa1008232
    [5]
    Bonow RO, Brown AS, Gillam LD, et al. CC/AATS/AHA/ ASE/EACTS HVS/SCA/SCAI/SCCT/SCMR/STS 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis. J Am Soc Echocardiogr 2018; 31: 117-147. doi: 10.1016/j.echo.2017.10.020
    [6]
    Frey N, Steeds RP, Rudolph TK, et al. Symptoms, disease severity and treatment of adults with a new diagnosis of severe aortic stenosis. Heart 2019; 105: 1709-1716.
    [7]
    Hermiller JB Jr, Yakubov SJ, Reardon MJ, et al. Predicting early and late mortality after transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 68: 343-352. doi: 10.1016/j.jacc.2016.04.057
    [8]
    Mack MJ, Holper EM. TAVR risk assessment does the eyeball test have 20/20 vision, or can we do better? J Am Coll Cardiol 2016; 68: 353-355. doi: 10.1016/j.jacc.2016.05.030
    [9]
    Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36: 3075-3128. doi: 10.1093/eurheartj/ehv319
    [10]
    Marquis-Gravel G, Redfors B, Leon MB, et al. Medical treatment of aortic stenosis. Circulation 2016; 134: 1766-1784. doi: 10.1161/CIRCULATIONAHA.116.023997
    [11]
    Chockalingam A, Venkatesan S, Subramaniam T, et al. Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis. Safety and efficacy of angiotensin converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004; 147: E19.
    [12]
    Dalsgaard M, Iversen K, Kjaergaard J, et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am Heart J 2014; 167: 226-234. doi: 10.1016/j.ahj.2013.11.002
    [13]
    Bull S, Loudon M, Francis JM, et al. A prospective, double- blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging 2015; 16: 834-841. doi: 10.1093/ehjci/jev043
    [14]
    Dahl JS, Videbak L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol 2010; 106: 713-719. doi: 10.1016/j.amjcard.2010.04.028
    [15]
    Helske-Suihko S, Laine M, Lommi J, et al. Is blockade of the renin-angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis? J Cardiovasc Pharmacol 2015; 65: 233-240. doi: 10.1097/FJC.0000000000000182
    [16]
    Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart 2018; 104: 644-651. doi: 10.1136/heartjnl-2017-311738
    [17]
    Saeeda S, Mancia G, Rajanic R, et al. Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis: Relationship with all-cause mortality. Int J Cardiol 2020; 298: 122-125. doi: 10.1016/j.ijcard.2019.09.007
    [18]
    Otto CM, Cooper S. Medical management of symptomatic aortic stenosis, 2019. https://www.uptodate.com/contents/medical-management-of-symptomatic-aortic-stenosis/print (accessed December 18, 2019).
    [19]
    Sawhney N, Hassankhani A, Greenberg BH, et al. Calcific Aortic Stenosis in the Elderly: A Brief Overview. Am J Geriatr Cardiol 2003; 12: 178-182. doi: 10.1111/j.1076-7460.2003.02070.x
    [20]
    Kang TS, Park S. Antihypertensive Treatment in Severe Aortic Stenosis. J Cardiovasc Imaging 2018; 26: 45-53. doi: 10.4250/jcvi.2018.26.e9
    [21]
    Hansson NH, Sörensen J, Harms HJ, et al. Metoprolol reduces hemodynamic and metabolic overload in asymptomatic aortic valve stenosis patients: a randomized trial. Circ Cardiovasc Imaging 2017; 10: e006557.
    [22]
    Rossi A, Temporelli PL, Cicoira M, et al. Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis. Int J Cardiol 2015; 190: 15-17. doi: 10.1016/j.ijcard.2015.04.083
    [23]
    Bang CN, Greve AM, Rosseb AB, et al. Antihypertensive treatment with β-blockade in patients with asymptomatic aortic stenosis and association with cardiovascular events, J Am Heart Assoc 2017; 6: e006709.
    [24]
    Stewart RA, Kerr AJ, Cowan BR, et al. ZEST Study Investigators. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J 2008; 156: 348-355. doi: 10.1016/j.ahj.2008.03.012
    [25]
    Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756-1763. doi: 10.1056/NEJMoa022021
    [26]
    Joanna Cowell S, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397. doi: 10.1056/NEJMoa043876
    [27]
    Dichtl W, Alber HF, Feuchtner GM, et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008; 102: 743-748. doi: 10.1016/j.amjcard.2008.04.060
    [28]
    Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356. doi: 10.1056/NEJMoa0804602
    [29]
    Van der Linde D, Yap SC, Van Dijk AP, et al. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). Am J Cardiol 2011; 108: 265-271. doi: 10.1016/j.amjcard.2011.03.032
    [30]
    Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of Aortic Stenosis Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121: 306-314. doi: 10.1161/CIRCULATIONAHA.109.900027
    [31]
    Antonini-Canterin F, Popescu BA, Huang G, et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 2005; 6: 119-124.
    [32]
    Lindman B. Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study (ASPEN), Clinical Trials. gov Identifier: NCT01275339. September 12, 2018. https://clinicaltrials.gov/ct2/show/NCT01275339 (Accessed November 30, 2019).
    [33]
    Bongiovanni D, Kühl C, Bleiziffer B, et al. Emergency treatment of decompensated aortic stenosis. Heart 2018; 104: 23-29. doi: 10.1136/heartjnl-2016-311037
    [34]
    Everett RJ, Clavel MA, Pibarot P, et al. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart 2018; 104: 2067-2076. doi: 10.1136/heartjnl-2017-312304
    [35]
    Goel SS, Ige M, Tuzcu EM, et al. Severe aortic stenosis and coronary artery disease implications for management in the transcatheter aortic valve replacement era. A comprehensive review. J Am Coll Cardiol 2013; 62: 1-10.
    [36]
    Dewey TM, Brown DL, Herbert MA, et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg 2010; 89: 758-767. doi: 10.1016/j.athoracsur.2009.12.033
    [37]
    Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J 2016; 37: 2645-2657. doi: 10.1093/eurheartj/ehw096
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Article Metrics

    Article views (84) PDF downloads(13) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return